[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-cancers":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,79,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100604335","phase-1-a-multi-site-break-through-cancer-trial-targeting-measurable-residual-disease-in-patients-with-acute-myeloid-leukemia-a-phase-12-study-of-tagraxofusp-azacitidine-and-venetoclax-100604335",false,"NCT07148180","A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1\u002F2 Study of Tagraxofusp, Azacitidine, and Venetoclax","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* History of known diagnosis of Acute Myeloid Leukemia (including de novo, secondary or AML arising from MDS).\n* Subjects must be in CR, CRi, or CRh with \\\u003C5% morphologic blasts in bone marrow\n* Any evidence of CD123+ by central assessment.\n* Participants must have measurable disease, defined as ≥ 0.1% by multiparametric flow cytometric assay as assessed by central laboratory\n* ECOG performance status ≤2 (see Appendix A).\n* Subjects must have adequate organ and marrow function as defined below:\n\n  * total bilirubin ≤ 1.5 x institutional upper limit of normal unless due to Gilbert or non-hepatic in origin\n  * AST(SGOT) and ALT(SGPT) ≤ 3.0 × institutional upper limit of normal\n  * Creatinine clearance ≥ 45 ml\u002Fmin GFR by MDRD\n* Albumin ≥ 3.2 g\u002FdL\n* Left ventricular ejection fraction ≥ institutional lower limit of normal by MUGA or echocardiogram within 30 days of first protocol treatment. This can be locally assessed.\n* Pregnancy potential: Female subjects of childbearing potential must have negative results for pregnancy test. Females with reproductive potential are advised to use effective contraception during study treatment and for at least 6 months after last dose. Similarly, males with female partners of reproductive potential are advised to use effective contraception during treatment and for at least 3 months after the last dose. Men must agree to abstain from donating sperm.\n* Subject is able and willing to adhere to the study visit schedule and other protocol requirements\n\nExclusion Criteria:\n\n* Prior treatment with CD123-targeted therapy\n* Known diagnosis of acute promyelocytic leukemia.\n* Subjects who received intensive anti-leukemic chemotherapy within 2 weeks from first dose of study. If on venetoclax, subjects must be off venetoclax for at least 5 days\n* Subjects pre-arranged for SCT are only excluded if it is imminent.\n* History of prior allogeneic stem cell transplant\n* Subject has uncontrolled, clinically significant pulmonary disease (e.g. COPD, pulmonary hypertension, etc.) that in the opinion of the Investigator would put the subject at significant risk for pulmonary complications during the study.\n* Subject has experienced Grade 3 or Grade 4 capillary leak syndrome (CLS) in the past for any reason\n* Subjects with known HBV and\u002For HCV infection must have undetectable viral load during screening (HBV and HCV testing are not required.) Participants with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.\n* Subjects with known HIV positivity are permitted provided they have undetectable viral load at the time of screening (HIV testing is not required).\n* Subject has a concurrent malignancy or prior malignancy within the 6-month period before screening. To be eligible, subjects must be in remission from the prior malignancy at least 6 months prior to screening and all treatment-related toxicities must have resolved to ≤ Grade 1 except for alopecia. Exceptions include adequately treated basal or squamous cell skin cancer, superficial bladder cancer, adequately treated carcinoma in situ of the cervix or uterus, or carcinoma in situ of the breast, previous malignancy confined and surgically resected (or successfully treated with other modalities) with curative intent, which are permissible for inclusion. Maintenance therapy, hormonal therapy, or steroid therapy for a well-controlled concurrent malignancy is allowed.\n* Subject has uncontrolled systemic fungal, bacterial, or viral infection, defined as ongoing signs\u002Fsymptoms related to the infection without improvement despite appropriate antibiotics, antivirals, or antifungals, either IV or oral. However, subjects with controlled infection still requiring anti-infectives are eligible.\n* Subjects with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, that have New York Heart Association Functional Class III or IV symptoms.\n* Subject has evidence of ongoing alcohol or drug abuse\n* Subjects with known active\u002Fsymptomatic CNS involvement. CNS prophylaxis allowed\n* Subjects receiving moderate or strong P450 3A (CYP3A) inducers within 7 days of start of study therapy. See Appendix B for examples\n* Subjects with uncontrolled intercurrent illness.\n* Administration or consumption of any of the following within 3 days prior to the first dose of study drug:\n\n  * grapefruit or grapefruit products\n  * Seville oranges (including marmalade containing Seville oranges)\n  * star fruit\n* Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with trial therapy, breastfeeding should be discontinued if the mother is treated on trial.","ALL","18 Years",{"count":18,"type":19},31,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This research study is to determine if the combination therapy can safely help to control residual Acute Myeloid Leukemia (AML) and to prevent disease recurrence.\n\nThe names of the study drugs involved in this study are:\n\n* Tagraxofusp (a type of CD123-directed cytotoxin)\n* Azacitidine (a type of standard of care cytidine nucleoside analog)\n* Venetoclax (a type of standard of care BCL-2 inhibitor)",[26,27,28,29],"Acute Myeloid Leukaemia (AML)","Leukemia","Blood Cancer","Blood Cancers",[31,32,33,34,28,29],"Acute Myeloid Leukemia","AML","Measurable Residual Disease","Myeloid Neoplasms","RECRUITING","2026-02-03",{"date":38,"type":39},"2026-02-05","ACTUAL",{"date":41,"type":39},"2026-02-02",{"date":43,"type":19},"2030-12-31",{"name":45,"class":46},"Jacqueline Garcia, MD","OTHER",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":20,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100538863","discovery-evaluating-a-decision-support-tool-for-adults-seen-in-hematologyoncology-clinics-100538863","NCT06296368","DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology\u002FOncology Clinics","DISCOVERY","Inclusion Criteria In order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\n1. Written or verbal informed consent obtained to participate in the study and HIPAA authorization for the release of personal health information.\n2. Subjects are willing and able to comply with study procedures based on the judgment of the investigator.\n3. Age ≥ 60 years at the time of consent.\n4. New patient to either the hematologic malignancies clinic or the bone marrow transplant\u002Fcellular therapy clinic.\n\nExclusion Criteria\n\nAll subjects meeting any of the exclusion criteria listed below at baseline will be excluded from study participation:\n\n1\\. Dementia, altered mental status, or psychiatric condition that would prohibit the understanding or rendering of informed consent or participation in the intervention.","60 Years",{"count":57,"type":19},500,[59],"NA","The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatment decisions compared to usual care.",[62,63,64,27,29],"Hematologic Malignancies","Lymphoma","Multiple Myeloma",[66,67,68],"decision support tool","pragmatic study","best-worst scaling","2026-01-26",{"date":71,"type":39},"2026-01-28",{"date":73,"type":39},"2024-06-21",{"date":75,"type":19},"2028-09-01",{"name":77,"class":46},"UNC Lineberger Comprehensive Cancer Center",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":97,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":47},"100145560","cibmtr-research-database-100145560","NCT01166009","CIBMTR Research Database","Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries","Eligibility to Participate in the Research Database\n\nRecipient Eligibility Criteria:\n\n* Any recipient of an unrelated or related donor or autologous HSC transplant in a CIBMTR center is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children.\n\nIndividual with Marrow Toxic Injury Eligibility Criteria:\n\n* Any individual who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Transplant Network (RITN) is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Eligible individuals may have received supportive care only, growth factor support, HSC transplant or other appropriate medical treatment for marrow toxic injury. Treatments applied are at the discretion of the care facility, and are not determined by the NMDP or CIBMTR.\n\nUnrelated Donor Eligibility Criteria:\n\n* All donors registered on the NMDP Registry who have been requested to donate a product for a recipient are eligible to participate in the Research Database.\n* All maternal cord blood donors are enrolled in the NMDP Cord Blood Bank Investigational New Drug (IND) protocol, and sign an informed consent document specific to that protocol. Data collected as part of the Cord Blood Bank protocol are included in the Research Database.",{"count":87,"type":19},99999999,"OBSERVATIONAL","The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies.\n\nA secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries.\n\nObjectives:\n\nTo learn more about what makes stem cell transplants and cellular therapies work well such as:\n\n* Determine how well recipients recover from their transplants or cellular therapy;\n* Determine how recovery after a transplant or cellular therapy can be improved;\n* Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy;\n* Determine how access to transplant or cellular therapy for different groups of patients can be improved;\n* Determine how well donors recover from the collection procedures.",[91,92,93,29,94,95,96],"Autologous Stem Cell Transplantation","Allogeneic Stem Cell Transplantation","Solid Tumors","CAR-T","Gene Therapy","Non-malignant Disease",[98,99,100,101,95,94],"Data Collection","CIBMTR","NMDP","Stem Cell Transplantation","2025-08-07",{"date":104,"type":39},"2025-08-12",{"date":106,"type":4},"2002-07",{"date":108,"type":19},"2050-07",{"name":110,"class":111},"Center for International Blood and Marrow Transplant Research","NETWORK",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":20,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":78},"100597444","lifestyle-intervention-for-veterans-with-blood-cancer-tele-intervention-100597444","NCT07058571","Lifestyle Intervention for Veterans With Blood Cancer: Tele-Intervention","Inclusion Criteria:\n\n* Living with blood cancer\n* Physically willing and able to perform 30-90 minutes of exercise a minimum of 2 times per week\n\nExclusion Criteria:\n\n* Veterans who are unable to perform 30-90 minutes of exercise twice a week\n* Veterans with significant disabilities related to balance or motion that would cause a safety risk\n* Veterans without a smart personal device (smart phone, tablet, or computer) and internet connection (for example, cellular or WIFI connection)\n* Veterans who are pregnant",{"count":119,"type":19},30,[59],"Background. This study aims to evaluate the effectiveness of a telehealth-mediated lifestyle intervention program tailored for veterans with blood cancer, focusing on improving health-related quality of life, mental health, and pain outcomes. The hypothesis posits that the telehealth-delivered program will lead to significant improvements in these areas, specifically targeting veterans undergoing treatment or in post-treatment phases.\n\nObjective. Recognizing the unique experiences of veterans, especially those in rural or underserved regions, this study seeks to provide insights into the feasibility and impact of telehealth-based lifestyle interventions for this distinct population.\n\nMethods. The pilot trial will enroll 30 veterans from the H. John Heinz III VA. Participants will complete baseline web-based surveys assessing demographics, occupational performance, and telehealth preparedness. The intervention comprises progressive resistance and aerobic exercises delivered via telehealth by a health coach, starting with a live supervised session followed by regular remote sessions. Each participant will engage in exercise sessions coordinated through the Veteran's Video Connect (VVC) application, with ongoing communication facilitated via email. This setup allows the health coach to adjust exercise intensity based on real-time symptom feedback.\n\nTo address potential technology literacy biases, the VVCMatch assessment will categorize veterans as \"technology prepared\" or in need of additional education. Those requiring support will receive guidance on using the VVC app before starting the intervention. Additionally, participants will receive dietary consultations from the Leukemia and Lymphoma Society, independent of the research team.\n\nOutcome measures include assessments of symptoms, fatigue, function, mental health, and pain, along with evaluations of the intervention's usability through surveys on perceived usefulness and ease of use. These assessments aim to detect meaningful changes and ensure the intervention's effectiveness and acceptability among veterans.",[29],[124,125,126,28],"Physical Activity","Exercise","Tele-oncology","2025-06-30",{"date":129,"type":39},"2025-07-10",{"date":131,"type":39},"2015-04-03",{"date":133,"type":19},"2026-05-31",{"name":135,"class":136},"VA Pittsburgh Healthcare System","FED"]